Atlas Trials

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Clinical trial NCT02841150 · COMPLETED

Trial details

NCT number
NCT02841150
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2016-06-01
Primary completion
2016-08-01
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.